This study is currently not recruiting participants.

A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer

Study of Investigational Medication for Previously Treated Breast Cancer

Not Recruiting
18 years - 100 years
Female
Phase N/A

Brief description of study.

This study plans to learn more about an investigational drug called ENMD-2076 and whether it can help patients with previously treated breast cancer.

Detailed description of study

This study plans to learn more about an investigational drug called ENMD-2076 and whether it can help patients with previously treated breast cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: 18 years - 100 years
  • Gender: Female

This study investigates an investigational medication for patients with previously treated breast cancer. Breast cancer is a disease where cells in the breast grow out of control. The purpose of this study is to learn more about the effects of this investigational medication on breast cancer that has been treated before.

Participants will receive the investigational medication and will be monitored to see how it affects their breast cancer. The study will involve regular check-ups and assessments to track the progress and any effects of the treatment.

  • Who can participate: Eligibility criteria will be provided by the study team.
  • Study details: Participants will take the investigational medication and attend regular appointments for monitoring. The study will include assessments to understand the effects of the treatment.
Updated on 19 Feb 2024. Study ID: 1207009094

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team